Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > 02162 KEYMED BIO-B > Company Profile
02162 KEYMED BIO-B
45.600
-0.300-0.65%
Symbol
02162
Company Name
KEYMED BIO-B
ISIN
KYG5252B1023
Listing Date
07/08/2021
Establishment Date
04/23/2018
Registration
Cayman Islands
Chairman
Bo CHEN
Secretary
Yanrong\tanbairu Zhang
Audit Institution
Ernst & Young accounting firm
Company Category
Overseas registration of Mainland Individuals control
Registered Office
Floor 4, Willow House, Cricket Square Grand Cayman KY1-9010 Cayman Islands
Head Office and Principal Place of Business
Room 1701, Block 2, Lippo Centre, Queensway, Hong Kong
Fiscal Year Ends
12-31
Employees
474
Market
Hong Kong motherboard
Business
Keymed Biosciences Inc is a Chinese biotechnology company. The company focuses on finding and developing innovative biotherapies to meet unmet medical needs in the field of autoimmunity and oncology therapy. The company has mastered in-house drug discovery and development technologies, including those that make up its innovative antibody discovery platform and its own new T cell redirection (nTCE) bispecific antibody platform. The company has also established a fully integrated platform covering key functions of biopharmaceutical development. The company's main products include CM310, CM326 and CMG901.
Profile
Konoya Biopharmaceutical Technology Co., Ltd. is a biotechnology company with a variety of clinical assets, each of which is a strong competitor in its respective competitive field. We focus on finding and developing innovative biotherapies to meet a large number of unmet medical needs in the field of autoimmunity and oncology therapy. With a strong foundation in biomedical research, we have mastered in-house drug discovery and development technologies, including our innovative antibody discovery platform and our own novel T cell redirection (nTCE) bispecific antibody platform. In less than five years since its establishment, we have consistently explored areas of disease treatment that are extremely challenging and in short supply. Now, we have more than ten drug candidates in the internal development stage, five of which are in the clinical stage. Our own products under research and development apply cutting-edge scientific discoveries and reflect our profound market insight. Health spending increased significantly in the first two decades of the new millennium driven by economic growth and the reform of the health care system. Due to the rapid development of urbanization, changes in residents' lifestyle and environmental changes, China's epidemiological focus is shifting from the prevalence of infectious diseases to the prevalence of cancer and other chronic diseases. These basic and evolving trends pose new challenges to public health and expose new areas of disease that are heavily burdened by inadequate treatments. To support our innovative research and development of biopharmaceuticals, we have established a fully integrated platform covering all key functions of biopharmaceutical development, including target verification, lead compound generation and optimization, preclinical evaluation, process development, transformation research, clinical development and production. This integrated platform enables us to quickly and cost-effectively discover, build, expand and advance our diversified pipeline of innovative and differentiated antibody therapy, including monoclonal antibodies, antibody-coupled drugs and bispecific antibodies.
Company Overview
Konoya Biopharmaceutical Technology Co., Ltd. is a biotechnology company with a variety of clinical assets, each of which is a strong competitor in its respective competitive field. We focus on finding and developing innovative biotherapies to meet a large number of unmet medical needs in the field of autoimmunity and oncology therapy. With a strong foundation in biomedical research, we have mastered in-house drug discovery and development technologies, including our innovative antibody discovery platform and our own novel T cell redirection (nTCE) bispecific antibody platform. In less than five years since its establishment, we have consistently explored areas of disease treatment that are extremely challenging and in short supply. Now, we have more than ten drug candidates in the internal development stage, five of which are in the clinical stage. Our own products under research and development apply cutting-edge scientific discoveries and reflect our profound market insight. Health spending increased significantly in the first two decades of the new millennium driven by economic growth and the reform of the health care system. Due to the rapid development of urbanization, changes in residents' lifestyle and environmental changes, China's epidemiological focus is shifting from the prevalence of infectious diseases to the prevalence of cancer and other chronic diseases. These basic and evolving trends pose new challenges to public health and expose new areas of disease that are heavily burdened by inadequate treatments. To support our innovative research and development of biopharmaceuticals, we have established a fully integrated platform covering all key functions of biopharmaceutical development, including target verification, lead compound generation and optimization, preclinical evaluation, process development, transformation research, clinical development and production. This integrated platform enables us to quickly and cost-effectively discover, build, expand and advance our diversified pipeline of innovative and differentiated antibody therapy, including monoclonal antibodies, antibody-coupled drugs and bispecific antibodies.
CEO: Bo CHEN
Market: Hong Kong motherboard
Listing Date: 07/08/2021
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist